Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss

PHASE2CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

June 30, 2016

Conditions
Age-Related Hearing Loss
Interventions
DRUG

AUT00063

600 mg, orally, once a day, for 4 weeks

DRUG

Placebo

orally, once a day, for 4 weeks

Trial Locations (13)

11042

Long Island Jewish Medical Center, New Hyde Park

27103

Piedmont Ear, Nose, & Throat Associates, Winston-Salem

28401

PMG Research Inc., Wilmington

33143

QPS MRA (Miami Research Associates), Miami

33487

ENT Associates of South Florida, Boca Raton

33620

University of South Florida, Tampa

37232

Vanderbilt University Medical Center, Nashville

39216

The University of Mississippi Medical Center, Jackson

40202

University of Louisville, Louisville

55095

Mayo Clinic, Rochester

80909

Colorado ENT and Allergy, Colorado Springs

84107

Jean Brown Research, Murray

95815

Sacramento ENT, Sacramento

Sponsors
All Listed Sponsors
lead

Autifony Therapeutics Limited

INDUSTRY

NCT02345031 - Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss | Biotech Hunter | Biotech Hunter